This is now a good possibility to ask about PBT2, and why ATH does not tell anything in any investor conferences about it. Another question I would like to ask is whether ATH has any info on how ATH434 works on mitochondrion level as PD and MSA are mitochondrion diseases. Unfortunately, it looks like I will not be able to take part in this conference. I hope that somebody else will ask these important questions.
Ann: Alterity to Present at Life Sciences Investor Forum, page-2
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(11.1%) |
Mkt cap ! $21.28M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $1.528K | 317.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 102 | 97511267 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 31179254 | 15 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |